Taehoon Kim

Mr. Taehoon Kim

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2026 in Cancers
Verified
Journal Article
Open access
PDF file
TKTaehoon Kim
Taehoon Kim
DSDongju Shin
Dongju Shin
HAHyun Kyu Ahn
Hyun Kyu Ahn
YMYoung Joon Moon
Young Joon Moon
DBDuhee Bang
Duhee Bang
KKKwang Hyun Kim
Kwang Hyun Kim
Early detection of bladder cancer poses a major challenge for liquid biopsy due to limited tumor burden and low abundance of tumor-derived DNA. In such low-signal settings, detection sensitivity critically depends on both biofluid selection and effective integration of weak, distributed molecular signals. We analyzed Enzymatic Methyl-seq (EM-seq) data on 41 matched urine–plasma pairs, which demonstrated that urine samples exhibited significantly higher tumor fractions and greater concordance with tissue methylation profiles than plasma. Based on this observation, we developed a urine-based bladder cancer detection framework using EM-seq. We profiled 143 urine samples (68 bladder cancer and 75 healthy controls) and 14 bladder cancer tissues. Methylation markers (113,052 regions) were identified by comparing cancer tissues (n = 14) with urine from healthy individuals (n = 14). Using XGBoost, possible features and their combinations were evaluated, with the combination of methylation and copy number variations (CNV) yielding the best performance as the final ensemble model. When evaluated on an independent test set, the model achieved 91.9% sensitivity at 80% specificity, with an area under the curve (AUC) of 0.932 for bladder cancer detection and 0.928 for non-muscle invasive bladder cancer (NMIBC) detection. Notably, the model successfully detected four of seven mutation-negative cases, demonstrating complementary value to mutation-based approaches.

24 July 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
HLHyeonseob Lim
Hyeonseob Lim
SJSoyeong Jun
Soyeong Jun
TKTaehoon Kim
Taehoon Kim
JLJi Hyun Lee
Ji Hyun Lee
DBDuhee Bang
Duhee Bang
Molecular barcoding methods enable high-sensitivity detection of circulating tumor DNA that is rarely present in liquid biopsy samples. Many methods involve ligation of molecular barcodes to DNA prior to hybridization capture, enabling recovery of starting molecules. Development of polymerase chain reaction (PCR)-based methods could facilitate more cost- and labor- effective detection; however, tracking molecular identity can be difficult, as new barcodes overwrite old barcodes in each cycle. Here, we present a sensitive genotyping method based on a peer-to-peer network-derived identifier for error reduction in amplicon sequencing (SPIDER-seq) and enable molecular identity tracking with PCR-derived libraries using overwritten barcodes. SPIDER-seq detected mutations at frequences as low as 0.125% after only two consecutive general PCR cycles and systematically analyzed the error pattern in the peer-to-peer network. Our method could facilitate the rapid detection of mutations associated with various cancers.

19 November 2025 in Scientific Reports
Verified
Journal Article
Open access
DSDongju Shin
Dongju Shin
TKTaehoon Kim
Taehoon Kim
JLJaywon Lee
Jaywon Lee
HKHwang-Phill Kim
Hwang-Phill Kim
TKTae-You Kim
Tae-You Kim
DBDuhee Bang
Duhee Bang
Aberrant DNA methylation drives cancer development, yet current screening methods require substantial resources for targeted enrichment across multiple CpG-rich regions. Early cancer detection in cell-free DNA (cfDNA) presents additional challenges due to low circulating tumor DNA fractions (0.01–10%) that dilute cancer-specific signals. To address these limitations, we developed Restriction Enzyme-based CpG-methylated fragment AmPlification sequencing (RECAP-seq) to selectively enrich hypermethylated fragments from existing Enzymatic Methyl-seq (EM-seq) libraries. RECAP-seq combines EM-seq library preparation with BstUI restriction enzyme digestion to target CGCG motifs, achieving preferential enrichment of CpG islands. With spike-in experiments using cell line mixtures, RECAP-seq successfully distinguished samples as low as 0.001%. The method identified 7,091 hypermethylated markers, including ALX4 which showed progressive increases with colorectal cancer stage. Clinical validation using cfDNA from 35 healthy donors and 47 colorectal cancer patients demonstrated robust detection with an area under the curve (AUC) of 0.932, achieving 78.7% sensitivity at 95% specificity.

12 March 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TKTaehoon Kim
Taehoon Kim
DBDuhee Bang
Duhee Bang
Whole-genome bisulfite sequencing (WGBS) provides multiple molecular information layers including methylation, copy number variations (CNVs), single nucleotide variants (SNVs), and fragmentome patterns in cell-free DNA (cfDNA) while gene fusion detection from WGBS data has not been widely explored. We applied a custom analysis pipeline using bisulfite-aware aligners supporting split read alignment to detect known gene fusions from WGBS data and validated this approach using cancer cell lines with characterized fusion events. Using K562 cells harboring the BCR-ABL1 fusion, WGBS-derived breakpoints showed concordance with WGS-derived coordinates. Serial dilution experiments with K562 DNA in NA12878 background at average 63X coverage established a limit of detection (LoD) of 8.1% fusion-positive DNA fraction, demonstrating 100% detection rate at ≥10%. Furthermore, our method with MCF-7 cells detected 10 of 12 validated fusions with high technical reproducibility (Pearson r > 0.99), including both inter-chromosomal and intra-chromosomal events. This approach confirms that known gene fusions can be reliably detected from WGBS data, particularly well-suited for applications where methylation and fusion profiling are both required.